FxCycle™ Based Ploidy Correlates with Cytogenetic Ploidy in B-Cell Acute Lymphoblastic Leukemia and Is Able to Detect the Aneuploid Minimal Residual Disease Clone.
BCP-ALL
DNA ploidy
FxCycle™ violet
MRD
cytogenetics
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
01
08
2018
revised:
08
12
2018
accepted:
07
01
2019
pubmed:
5
2
2019
medline:
1
9
2020
entrez:
5
2
2019
Statut:
ppublish
Résumé
Flow cytometry (FCM) is a simple, sensitive, and specific technique that can potentially determine DNA ploidy in B-cell precursor ALL (BCP-ALL) and is complementary to cytogenetics. A prospective FCM DNA ploidy analysis using FxCycle™ Violet (assay sensitivity 0.01%) was done in 125 consecutive new cases of BCP-ALL (90 cases <15 years of age) and compared with corresponding cytogenetic ploidy (karyotyping and/or FISH) data wherever available. This assay was also subsequently evaluated for detection of residual aneuploid clone in few BCP-ALL cases. Of the total 125 BCP-ALL cases evaluated, flow ploidy analysis revealed diploidy (DI 0.96-1.05) in 44.8% (n = 56), low-hyperdiploidy (DI 1.06 to 1.15) in 13.6% (n = 17), high-hyperdiploidy (DI 1.16-1.39) in 32.8% (n = 41) and near-tetraploidy (DI ≥ 1.80) in 2.4% (n = 3) cases. The high risk sub-group of low-hypodiploidy (DI 0.70 to 0.88)/near-triploidy (DI 1.40 to 1.79) constituted 5.6% (n = 7) cases while there was only one case with haploidy (DI 0.58). Overall, high concordance of 90.4% (n = 113) was noted between the combined cytogenetics ploidy and FCM ploidy. Of the total discordant cases (n = 12), the maximum discordance was seen in the low-hyperdiploid DI subgroup (n = 10), which included seven cases with low DNA index high hyperdiploidy (LDI-HHD). FCM DNA ploidy assay was able to detect the residual clone in all six MRD positive aneuploid cases evaluated. FxCycle™ based DNA ploidy ascertains strong correlation with cytogenetic profiles and yields complementary information that can be used by the cytogenetics laboratories or otherwise. © 2019 International Clinical Cytometry Society.
Sections du résumé
BACKGROUND
Flow cytometry (FCM) is a simple, sensitive, and specific technique that can potentially determine DNA ploidy in B-cell precursor ALL (BCP-ALL) and is complementary to cytogenetics.
METHODS
A prospective FCM DNA ploidy analysis using FxCycle™ Violet (assay sensitivity 0.01%) was done in 125 consecutive new cases of BCP-ALL (90 cases <15 years of age) and compared with corresponding cytogenetic ploidy (karyotyping and/or FISH) data wherever available. This assay was also subsequently evaluated for detection of residual aneuploid clone in few BCP-ALL cases.
RESULTS
Of the total 125 BCP-ALL cases evaluated, flow ploidy analysis revealed diploidy (DI 0.96-1.05) in 44.8% (n = 56), low-hyperdiploidy (DI 1.06 to 1.15) in 13.6% (n = 17), high-hyperdiploidy (DI 1.16-1.39) in 32.8% (n = 41) and near-tetraploidy (DI ≥ 1.80) in 2.4% (n = 3) cases. The high risk sub-group of low-hypodiploidy (DI 0.70 to 0.88)/near-triploidy (DI 1.40 to 1.79) constituted 5.6% (n = 7) cases while there was only one case with haploidy (DI 0.58). Overall, high concordance of 90.4% (n = 113) was noted between the combined cytogenetics ploidy and FCM ploidy. Of the total discordant cases (n = 12), the maximum discordance was seen in the low-hyperdiploid DI subgroup (n = 10), which included seven cases with low DNA index high hyperdiploidy (LDI-HHD). FCM DNA ploidy assay was able to detect the residual clone in all six MRD positive aneuploid cases evaluated.
CONCLUSIONS
FxCycle™ based DNA ploidy ascertains strong correlation with cytogenetic profiles and yields complementary information that can be used by the cytogenetics laboratories or otherwise. © 2019 International Clinical Cytometry Society.
Identifiants
pubmed: 30715800
doi: 10.1002/cyto.b.21765
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-367Informations de copyright
© 2019 International Clinical Cytometry Society.
Références
Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A pediatric oncology group study. J Clin Oncol. 1992;10:606-613.
Smets LA, Slater R, van Wering ER, van der Does-van den Berg A, Hart AA, Veerman AJ, Kamps WA. DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: A report from studies ALL V, ALL VI, and ALL VII (1979-1991) of the Dutch childhood leukemia study group and The Netherlands workgroup on cancer genetics and Cytogenetics. Med Pediatr Oncol. 1995;25:437-444.
Raimondi SC, Zhou Y, Shurtleff SA, Rubnitz JE, Pui C-H, Behm FG. Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: Association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet. 2006;169:50-57.
Tembhare P, Badrinath Y, Ghogale S, Patkar N, Dhole N, Dalavi P, Kunder N, Kumar A, Gujral S, Subramanian PG. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A. 2016;89:281-291.
Wang XM. Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia. Transl Pediatr. 2014;3:149-155.
Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:991-1010. v.
Amare PSK, Jain H, Kabre S, Deshpande Y, Pawar P, Banavali S, Menon H, Sengar M, Arora B, Khattry N, et al. Cytogenetic profile in 7209 Indian patients with de novo acute leukemia: A single Centre study from India. J Cancer Ther. 2016;07:530-544.
Darzynkiewicz Z. Critical aspects in analysis of cellular DNA content. Curr Protoc Cytom. 2011 Apr;56(1):7-2.
Plander M, Brockhoff G, Barlage S, Schwarz S, Rothe G, Knuechel R. Optimization of three- and four-color multiparameter DNA analysis in lymphoma specimens. Cytometry A. 2003;54:66-74.
Krishan A. Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Methods Cell Biol. 1990;33:121-125.
www.lifetechnologies.com/order/catalog/product/F10347.
Tembhare P, Badrinath Y, Ghogale S, Subramanian PG. Method for DNA Ploidy analysis along with Immunophenotyping for rare populations in a sample using FxCycle violet. Curr Protoc Cytom. 2017;80:6.38.1-6.38.15.
Nowak R, Oelschlaegel U, Schuler U, Zengler H, Hofmann R, Ehninger G, Andreeff M. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry. 1997;30:47-53.
Zwick D, Cooley L, Hetherington M. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: A retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods. Lab Hematol. 2006;12:75-81.
Kenney B, Zieske A, Rinder H, Smith B. DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49:42-48.
Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162:606-620.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017.
Pawar RN, Banerjee S, Bramha S, Krishnan S, Bhattacharya A, Saha V, Chakrapani A, Bhave S, Chandy M, Nair R, et al. Mixed-phenotypic acute leukemia series from tertiary care center. Indian J Pathol Microbiol. 2017;60:43-49.
Parihar M, Gupta A, Remani AS, Bhattacharyya A, Mishra DK, Chandy M. Novel t(2;12)(q31;p13) in a case of pediatric T-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2014;36:e313-e315.
Rachieru-Sourisseau P, Baranger L, Dastugue N, Robert A, Geneviève F, Kuhlein E, Chassevent A. DNA index in childhood acute lymphoblastic leukaemia: A karyotypic method to validate the flow cytometric measurement. Int J Lab Hematol. 2010;32:288-298.
Charrin C, Thomas X, Ffrench M, Le Q, Andrieux J, Mozziconacci M, Laï J. Hypodiploidy with 30-39 chromosomes and near-triploidy: two possible expressions of a sole entity conferring poor prognosis in Adult Acute Lymphoblastic Leukemia (ALL). A report from the LALA-94 and LALA-SA Groups: 35.
Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128:911-922.
Dastugue N, Suciu S, Plat G, Speleman F, Cavé H, Girard S, Bakkus M, Pagès MP, Yakouben K, Nelken B, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood. 2013;121:2415-2423.
Zaliova M, Hovorkova L, Vaskova M, Hrusak O, Stary J, Zuna J. Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16. Genes Chromosomes Cancer. 2016;55:727-737.
Kumar BK, Bhatia P, Trehan A, Singh AP, Kaul D, Bansal D. DNA Ploidy and S-phase Fraction Analysis in Paediatric B-cell Acute Lymphoblastic Leukemia Cases: A Tertiary Care Centre Experience. Asian Pac J Cancer Prev. 2015;16(17):7917-22.
Padhi S, Sarangi R, Mohanty P, Das R, Chakravarty S, Mohanty R, Jacob RT. Cytogenetic profile of pediatric acute lymphoblastic leukemia (ALL): Analysis of 31 cases with review of literature. Caryologia. 2011 Jan 1;64(1):33-41.
Stark B, Jeison M, Gobuzov R, Krug H, Glaser-Gabay L, Luria D, El-Hasid R, Harush MB, Avrahami G, Fisher S, et al. Near haploid childhood acute lymphoblastic leukemia masked by hyperdiploid line: Detection by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2001;128:108-113.
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. ESMO guidelines committee. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncologia. 2016;27:v69-v82.
Nowak R, Oelschlägel U, Hofmann R, Zengler H, Huhn R. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk Res. 1994;18:897-901.
Swerts K, Van Roy N, Benoit Y, Laureys G, Philippé J. DRAQ5: Improved flow cytometric DNA content analysis and minimal residual disease detection in childhood malignancies. Clin Chim Acta. 2007;379:154-157.